Wegovy maker Novo Nordisk cuts profit forecast as US prescriptions tail off
by Julia Kollewe from US news | The Guardian on (#6X43H)
Slowdown will deepen concerns Denmark's biggest company is losing market share to US rival Eli Lilly
Denmark's Novo Nordisk has cut its annual revenue and profit forecasts after disappointingly flabby" sales of its weight loss drug Wegovy, as US prescriptions tailed off amid fierce competition.
A boom in sales of Wegovy and the diabetes medication Ozempic helped to turn the pharmaceutical firm into Europe's most valuable listed company, worth $615bn at its peak.
Continue reading...